Author:
Gullo G.,Zuradelli M.,Sclafani F.,Santoro A.,Crown J.
Reference5 articles.
1. When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?;Beda;Tumori,2007
2. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy;Maciá Escalante;Clin Transl Oncol,2006
3. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000
4. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
5. First results of the NeoALTTO Trial (BIG 01-06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer;Baselga;Cancer Res,2011
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献